| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11095-016-2001-6 |
| P8608 | Fatcat ID | release_23re4ndehfcffgodlqvx2fn4le |
| P698 | PubMed publication ID | 27439505 |
| P2093 | author name string | Gian P Camenisch | |
| P2860 | cites work | Clearance mechanism assignment and total clearance prediction in human based upon in silico models | Q43848558 |
| Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight | Q47278853 | ||
| Shapes of membrane permeability-lipophilicity curves: extension of theoretical models with an aqueous pore pathway. | Q52232875 | ||
| SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin | Q57825149 | ||
| Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat | Q82100906 | ||
| Physicochemical determinants of human renal clearance | Q83838839 | ||
| The BCS, BDDCS, and regulatory guidances | Q83857470 | ||
| A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability | Q28293773 | ||
| New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data. | Q31053819 | ||
| Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions | Q34190909 | ||
| BDDCS applied to over 900 drugs | Q34206152 | ||
| Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system | Q34403502 | ||
| BDDCS class prediction for new molecular entities | Q34634883 | ||
| Quantitative structure-pharmacokinetic relationships for the prediction of renal clearance in humans | Q34785494 | ||
| Clinical Pharmacokinetics of Atorvastatin | Q35553211 | ||
| The use of BDDCS in classifying the permeability of marketed drugs | Q36634723 | ||
| The role of transporters in the pharmacokinetics of orally administered drugs | Q37537018 | ||
| Physiologically based pharmacokinetics (PBPK). | Q37550553 | ||
| Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption | Q38056878 | ||
| The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development | Q38059421 | ||
| BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs | Q38640797 | ||
| BDDCS, the Rule of 5 and drugability | Q38835159 | ||
| Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS). | Q38855314 | ||
| In vitro-in vivo extrapolation method to predict human renal clearance of drugs. | Q39022819 | ||
| The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans | Q39809409 | ||
| Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins | Q40916355 | ||
| Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions | Q41148725 | ||
| Predicting when biliary excretion of parent drug is a major route of elimination in humans | Q42846727 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 2583-2593 | |
| P577 | publication date | 2016-07-20 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts | |
| P478 | volume | 33 |
| Q63349796 | Advancing internal exposure and physiologically-based toxicokinetic modeling for 21st-century risk assessments |
| Q38849270 | Current In Vitro Methods to Determine Hepatic Kpuu: A Comparison of Their Usefulness and Limitations |
| Q49551182 | Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics. |
| Q47163195 | Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats |
| Q53824747 | Improving Prediction of Metabolic Clearance Using Quantitative Extrapolation of Results Obtained From Human Hepatic Micropatterned Cocultures Model and by Considering the Impact of Albumin Binding. |
| Q56392055 | Rapid experimental measurements of physicochemical properties to inform models and testing |
| Q91368246 | Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation |
| Q92730578 | Use of imaging to assess the activity of hepatic transporters |
Search more.